To evaluate reports of altered diagnostic images with fluorodeoxyglucose F18 (FDG) positron emission tomography (PET) after treatment with colony-stimulating factors (CSFs).
DATA SOURCES:
Literature was identified by a MEDLINE search (1966–December 2001). Key search terms included granulocyte colony-stimulating factor, granulocyte—macrophage colony-stimulating factor, macrophage colony-stimulating factor, fluorodeoxyglucose, and emission-computed tomography. English language literature was reviewed.
DATA SYNTHESIS:
Reports have suggested altered FDG PET images following CSF treatment. Studies that assessed the effect of CSF administration on FDG PET imaging of the bone and bone marrow were reviewed.
CONCLUSIONS:
Administration of CSFs may interfere with accurate FDG PET imaging. Separating FDG PET imaging from CSF therapy by ≥5 days may diminish this interference.
MoogFKotzerkeJReskeSN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med1999;40: 1407–13.
2.
KoleACNiewegOEHoekstraHJvan HornJRKoopsHSVaalburgW. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med1998;39: 810–5.
3.
SokoloffLReivichMKennedyCDes RosiersMHPatlakCSPettigrewKDThe [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem1977;28: 897–916.
4.
RoweJMAndersenJWMazzaJJBennettJMPaiettaEHayesFAA randomized placebo-controlled Phase III study of granulocyte—macrophage colony-stimulating factor in adult patients (<55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood1995;86: 457–62.
5.
NemunaitisJRabinoweSNSingerJWBiermanPJVoseJMFreedmanASRecombinant granulocyte—macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med1991;324: 1773–8.
6.
HeilGHoelzerDSanzMALechnerKYinLiu JAPapaGA randomized, double-blind, placebo-controlled, Phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood1997;90: 4710–8.
7.
FletcherBDWallJEHannaSL. Effect of hematopoietic growth factors on MR images of bone marrow in children undergoing chemotherapy. Radiology1993;189: 745–51.
8.
StokkelMPMOlmosValdes RAHoefnagelCARichelDJ. Tumor and therapy associated abnormal changes on bone scintigraphy. Old and new phenomena. Clin Nucl Med1993;18: 821–8.
9.
Abdel-DayemHMSanchezJAl-MohannadiSKempfJ. Diffuse thallium-201-chloride uptake in hypermetabolic bone marrow following treatment with granulocyte stimulating factor. J Nucl Med1992;33: 2014–6.
10.
IversenPONicolaysenGBenestadHB. The leukopoietic cytokine granulocyte colony—stimulating factor increases blood flow to rat bone marrow. Exp Hematol1993;21: 231–5.
11.
YaoWJHohCKHawkinsRAGlapsyJAWeilJALeeSJQuantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med1994;36: 794–9.
12.
KnoppMVBischoffHRimacAOberdorferFvan KaickG. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: Initial evaluation. Nucl Med Biol1996;23: 845–9.
13.
HollingerEFAlibazogluHAliAGreenALamonicaG. Hematopoietic cytokine mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med1997;23: 93–8.
14.
SugawaraYFisherSJZasadnyKRKisonPVBakerLHWahlRL. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol1998;16: 173–80.
15.
GundlapalliSOjhaBMountzJM. Granulocyte colony—stimulating factor confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med2002;27: 140–1.
16.
WahlRLHenryCAEthierSP. Serum glucose: Effect on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology1992;183: 643–7.
17.
SugawaraYZasadnyKRKisonPVBakerLHWahlRL. Splenic fluorodeoxyglucose uptake increased by granulocyte colony—stimulating factor therapy: PET imaging results. J Nucl Med1999;40: 1456–62.
18.
ZasadnyKRWahlRL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: Variations with body weight and a method for correction. Radiology1993;189: 847–50.
19.
DippoldWBernhardHBuschenfeldeMeyer KH. Immunological response to intrathecal and systemic treatment with ganglioside antibody R-24 in patients with malignant melanoma. Eur J Cancer1994;30A:137–44.
20.
KirkwoodJMMascariRAEdingtonHDRabkinMSDayRSWhitesideTLAnalysis of therapeutic and immunologic effects of R (24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer2000;88: 2693–702.
